Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

The agreement will lower the cost of certain drugs for asthma, some cancers, HIV and Type 2 diabetes, among other conditions.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for another condition, the drugmaker said on Tuesday. The ...

A monthly injection could help people with severe asthma come off daily steroid tablets entirely without any impact on symptoms, a trial has found. Tezepelumab – also known as Tezspire and made by ...